Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

詳細記述

保存先:
書誌詳細
出版年:Clin Sarcoma Res
主要な著者: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://ncbi.nlm.nih.gov/pubmed/31911828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-019-0123-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料